司帕沙星对革兰氏阴性菌和革兰氏阳性菌的作用机制及耐药机制。
Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.
作者信息
Piddock L J, Zhu M
机构信息
Antimicrobial Agents Research Group, Medical School, University of Birmingham, United Kingdom.
出版信息
Antimicrob Agents Chemother. 1991 Nov;35(11):2423-7. doi: 10.1128/AAC.35.11.2423.
Abstract
The inhibition of DNA synthesis by sparfloxacin; accumulation of sparfloxacin into members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and staphylococci; induction of recA in Escherichia coli; and the optimum bactericidal concentration (OBC) were measured, and killing kinetics at the OBC were estimated. The OBC and maximum recA-inducing concentration in E. coli were both 1 microgram of sparfloxacin per ml. Accumulation was rapid; two- to threefold more sparfloxacin than ciprofloxacin accumulated in staphylococci and more sparfloxacin accumulated in staphylococci than in gram-negative bacteria. Laboratory mutants with decreased susceptibilities to quinolones alone or multiply resistant were selected from the Enterobacteriaceae and Staphylococcus aureus by using sparfloxacin.
摘要
测定了司帕沙星对DNA合成的抑制作用；司帕沙星在肠杆菌科细菌、铜绿假单胞菌和葡萄球菌中的蓄积情况；大肠杆菌中recA的诱导情况以及最佳杀菌浓度（OBC），并估计了在OBC时的杀菌动力学。大肠杆菌中的OBC和recA诱导的最大浓度均为每毫升1微克司帕沙星。蓄积迅速；葡萄球菌中司帕沙星的蓄积量比环丙沙星多两到三倍，且葡萄球菌中司帕沙星的蓄积量比革兰氏阴性菌多。通过使用司帕沙星，从肠杆菌科细菌和金黄色葡萄球菌中筛选出了对喹诺酮类药物敏感性降低或多重耐药的实验室突变株。
相似文献
1
Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.司帕沙星对革兰氏阴性菌和革兰氏阳性菌的作用机制及耐药机制。
Antimicrob Agents Chemother. 1991 Nov;35(11):2423-7. doi: 10.1128/AAC.35.11.2423.
2
Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
J Antimicrob Chemother. 1993 Jun;31(6):855-63. doi: 10.1093/jac/31.6.855.
3
Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.Bay y3118对喹诺酮敏感及耐药革兰氏阴性菌和革兰氏阳性菌的活性。
Antimicrob Agents Chemother. 1994 Mar;38(3):422-7. doi: 10.1128/AAC.38.3.422.
4
Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
J Chemother. 1992 Feb;4(1):12-5. doi: 10.1080/1120009x.1992.11739131.
5
In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
Chemotherapy. 1992;38(2):99-106. doi: 10.1159/000238948.
6
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.司帕沙星、环丙沙星、氧氟沙星及其他抗生素对革兰氏阳性球菌血流感染分离株的体外活性
Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k.
7
In vitro activity of sparfloxacin and six reference antibiotics against gram-positive bacteria.司帕沙星与六种对照抗生素对革兰氏阳性菌的体外活性
Chemotherapy. 1991;37(4):275-82. doi: 10.1159/000238867.
8
In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.新型8-甲氧基喹诺酮BAY 12-8039的体外活性
Chemotherapy. 1996 Nov-Dec;42(6):410-25. doi: 10.1159/000239474.
9
Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.格雷帕沙星、环丙沙星、氧氟沙星和氟罗沙星的抗菌活性。
J Chemother. 1997 Feb;9(1):9-16. doi: 10.1179/joc.1997.9.1.9.
10
In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.司帕沙星、妥舒沙星、环丙沙星和氟罗沙星的体外活性。
Antimicrob Agents Chemother. 1991 May;35(5):955-60. doi: 10.1128/AAC.35.5.955.
引用本文的文献
1
Photosensitizer-specific bacterial stress responses in Escherichia coli reveal distinct targets in photoinduced inactivation.
Commun Biol. 2025 Oct 1;8(1):1413. doi: 10.1038/s42003-025-08881-4.
2
A Robust One-Step Recombineering System for Enterohemorrhagic .一种用于肠出血性大肠杆菌的强大一步重组工程系统
Microorganisms. 2022 Aug 23;10(9):1689. doi: 10.3390/microorganisms10091689.
3
A Novel Device-Integrated Drug Delivery System for Local Inhibition of Urinary Tract Infection.一种用于局部抑制尿路感染的新型装置集成药物递送系统。
Front Microbiol. 2021 Jun 25;12:685698. doi: 10.3389/fmicb.2021.685698. eCollection 2021.
4
Unique features of apicoplast DNA gyrases from Toxoplasma gondii and Plasmodium falciparum.来自刚地弓形虫和恶性疟原虫的顶质体DNA促旋酶的独特特征。
BMC Bioinformatics. 2014 Dec 19;15(1):416. doi: 10.1186/s12859-014-0416-9.
5
Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus.新型耐环丙沙星、对萘啶酸敏感的金黄色葡萄球菌突变体
Antimicrob Agents Chemother. 2002 Jul;46(7):2276-8. doi: 10.1128/AAC.46.7.2276-2278.2002.
6
Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.野生型或外排突变型肺炎链球菌对10种氟喹诺酮类药物的蓄积情况。
Antimicrob Agents Chemother. 2002 Mar;46(3):813-20. doi: 10.1128/AAC.46.3.813-820.2002.
7
A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.一种用于评估肺炎链球菌和金黄色葡萄球菌中氟喹诺酮类药物外排可能参与情况的便捷检测方法：莫西沙星、司帕沙星和曲伐沙星外排减少的证据
Antimicrob Agents Chemother. 2000 Mar;44(3):798-801. doi: 10.1128/AAC.44.3.798-801.2000.
8
Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.司帕沙星。对其在下呼吸道感染中的抗菌活性、药代动力学特性、临床疗效及耐受性的综述。
Drugs. 1997 Apr;53(4):700-25. doi: 10.2165/00003495-199753040-00010.
9
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.结核分枝杆菌H37Ra实验室筛选的耐氟喹诺酮突变体中的gyrase突变。
Antimicrob Agents Chemother. 1996 Aug;40(8):1768-74. doi: 10.1128/AAC.40.8.1768.
10
Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients.从两名患者身上分离出的鼠伤寒沙门氏菌临床分离株对环丙沙星的耐药性。
Antimicrob Agents Chemother. 1993 Apr;37(4):662-6. doi: 10.1128/AAC.37.4.662.
本文引用的文献
1
Genetic control of DNA initiation in Escherichia coli.大肠杆菌中DNA起始的遗传控制。
J Mol Biol. 1973 Feb 25;74(2):205-21. doi: 10.1016/0022-2836(73)90107-1.
2
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.大肠杆菌K-12耐诺氟沙星突变体的分离与鉴定
Antimicrob Agents Chemother. 1986 Aug;30(2):248-53. doi: 10.1128/AAC.30.2.248.
3
Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12.早期DNA合成抑制与羧基喹诺酮类抗菌剂对野生型和突变型[gyrA nfxB(ompF) acrA]大肠杆菌K-12的最低抑菌浓度（MICs）和最低杀菌浓度（MBCs）之间的关联。
Antimicrob Agents Chemother. 1988 Aug;32(8):1113-8. doi: 10.1128/AAC.32.8.1113.
4
Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa.诺氟沙星对铜绿假单胞菌DNA代谢的影响。
Antimicrob Agents Chemother. 1986 Jan;29(1):1-6. doi: 10.1128/AAC.29.1.1.
5
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.大肠杆菌中诺氟沙星耐药性的遗传与生化特征分析
Antimicrob Agents Chemother. 1986 Apr;29(4):639-44. doi: 10.1128/AAC.29.4.639.
6
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.由四环素或氯霉素筛选出的多重耐药性（Mar）大肠杆菌对氟喹诺酮类药物的交叉耐药性：除了外膜孔蛋白F（OmpF）减少外，药物积累减少与膜变化有关。
Antimicrob Agents Chemother. 1989 Aug;33(8):1318-25. doi: 10.1128/AAC.33.8.1318.
7
Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.大肠杆菌中喹诺酮耐药机制：nfxB和cfxB的特性，两个降低诺氟沙星蓄积的突变耐药位点
Antimicrob Agents Chemother. 1989 Mar;33(3):283-90. doi: 10.1128/AAC.33.3.283.
8
Fluorometric assay for fleroxacin uptake by bacterial cells.细菌细胞摄取氟罗沙星的荧光测定法。
Antimicrob Agents Chemother. 1989 Jan;33(1):27-9. doi: 10.1128/AAC.33.1.27.
9
Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin.司帕沙星（CI-978；AT-4140）、氧氟沙星和环丙沙星的抗葡萄球菌活性。
Antimicrob Agents Chemother. 1990 Sep;34(9):1843-5. doi: 10.1128/AAC.34.9.1843.
10
Mechanism of action of lomefloxacin.洛美沙星的作用机制。
Antimicrob Agents Chemother. 1990 Jun;34(6):1088-93. doi: 10.1128/AAC.34.6.1088.
Zotero 插件